Menu
Celularity warns 'substantial portion' of staff about possible layoffs after reviewing cell therapy strategy January 27, 2023 2:21 am https://www.fiercebiotech.com/biotech/celularity-warns-substantial-portion-staff-about-possible-layoffs-after-reviewing-cell
XyloCor gene therapy hits goals, paving way for phase 3 in cardiovascular space with no current treatment January 26, 2023 8:05 am https://www.fiercebiotech.com/biotech/xylocor-gene-therapy-hits-goals-paving-way-phase-3-cardiovascular-space-no-current
2 deals in 2 weeks: GenKOre signs pacts worth up to $650M biobucks for gene-editing tech January 26, 2023 6:33 am https://www.fiercebiotech.com/biotech/2-deals-2-weeks-genkore-signs-pacts-worth-650m-biobucks-gene-editing-tech
As Sesen investors allege a 'bribe' was offered to support planned Carisma merger, company says they’re ‘opportunists’ January 26, 2023 6:12 am https://www.fiercebiotech.com/biotech/sesen-investors-allege-being-bribed-support-planned-carisma-merger-company-says-theyre
Sanofi dives deeper into phase 3 data for Hemlibra rival as FDA decision approaches January 26, 2023 5:26 am https://www.fiercebiotech.com/biotech/sanofi-dives-deeper-phase-3-data-hemlibra-rival-fda-decision-approaches
Early data from AC Immune Alzheimer's vaccine suggests a response, setting up next phase of study January 26, 2023 5:24 am https://www.fiercebiotech.com/biotech/ac-immune-shares-climb-early-alzheimers-vaccine-data-suggests-response
Each year Eye on FDA provides a look-back to see what the agency was talking about and what has changed over time. This year is a telling one and FDA may be changing the nature of the way they are communicating with the public. Moreover, this year is marked by the fact that the agency …
What They Said – Looking Back at FDA Press Releases During 2022 Read More »
Miss for Aridis as antibody flunks undersized phase 3 pneumonia trial January 26, 2023 4:27 am https://www.fiercebiotech.com/biotech/miss-aridis-antibody-flunks-undersized-phase-3-pneumonia-trial
Ocuphire still focused on FDA approval despite diabetic eye drug missing phase 2 endpoint January 26, 2023 1:56 am https://www.fiercebiotech.com/biotech/ocuphire-still-focused-fda-meeting-after-diabetic-eye-drug-misses-phase-2-endpoint
After dose de-escalation, death drives Magenta to pause antibody-drug conjugate leukemia trial January 26, 2023 1:37 am https://www.fiercebiotech.com/biotech/after-dose-de-escalation-death-drives-magenta-pause-antibody-drug-conjugate-leukemia-trial
Medical Innovation Exchange @ Copywrite 2021. All Rights Reserved.